| Title |
Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer
|
|---|---|
| Published in |
OncoTargets and therapy, March 2013
|
| DOI | 10.2147/ott.s42245 |
| Pubmed ID | |
| Authors |
Eftimia Boutsikou, Theodoros Kontakiotis, Paul Zarogoulidis, Kaid Darwiche, Ellada Eleptheriadou, Konstantinos Porpodis, Grammati Galaktidou, Leonidas Sakkas, Wolfgang Hohenforst-Schmidt, Kosmas Tsakiridis, Theodoros Karaiskos, Konstantinos Zarogoulidis |
| Abstract |
Bevacizumab and erlotinib have been demonstrated to prolong overall survival in patients with non-squamous non-small cell lung cancer (NSCLC). We designed a four-arm Phase III trial to evaluate the efficacy and toxicity of the combination of docetaxel, carboplatin, bevacizumab, and erlotinib in the first-line treatment of patients with NSCLC. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 40 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 9 | 23% |
| Other | 5 | 13% |
| Student > Bachelor | 4 | 10% |
| Researcher | 4 | 10% |
| Student > Postgraduate | 3 | 8% |
| Other | 7 | 18% |
| Unknown | 8 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 40% |
| Biochemistry, Genetics and Molecular Biology | 2 | 5% |
| Chemistry | 2 | 5% |
| Psychology | 2 | 5% |
| Nursing and Health Professions | 2 | 5% |
| Other | 8 | 20% |
| Unknown | 8 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 March 2013.
All research outputs
#20,110,957
of 25,584,565 outputs
Outputs from OncoTargets and therapy
#1,438
of 2,967 outputs
Outputs of similar age
#153,038
of 206,591 outputs
Outputs of similar age from OncoTargets and therapy
#18
of 22 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,967 research outputs from this source. They receive a mean Attention Score of 3.0. This one is in the 46th percentile – i.e., 46% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 206,591 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.